Cancer metabolism pipeline breaks new ground

Overview of attention for news story in Nature Reviews Drug Discovery

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

So far, Altmetric has seen 24 X posts from 21 X users, with an upper bound of 83,496 followers.

RT @AsherMullard: Approval of Agios's enasidenib validates cancer metabolism targets. But its an outlier @NatRevDrugDisc https://t.co/Tp8Gb…

RT @AsherMullard: Approval of Agios's enasidenib validates cancer metabolism targets. But its an outlier @NatRevDrugDisc https://t.co/Tp8Gb…

RT @AsherMullard: Approval of Agios's enasidenib validates cancer metabolism targets. But its an outlier @NatRevDrugDisc https://t.co/Tp8Gb…

RT @AsherMullard: Approval of Agios's enasidenib validates cancer metabolism targets. But its an outlier @NatRevDrugDisc https://t.co/Tp8Gb…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 20 additional X posts.